EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial

Annabelle M Warren iD, Mathis Grossmann iD, Rudolf Hoermann iD, Rose Lin iD, Jeffrey D Zajac iD, Nicholas Russell iD

The Journal of Clinical Endocrinology & Metabolism · 21.01.2026 · 111 (2) · 341-347

DOI: 10.1210/clinem/dgaf428 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.07.2025. Verfasst von Annabelle M Warren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Austin Health Department of Endocrinology, Austin Health, Heidelberg, VIC 3084, Australia. Hauptthemen laut MEDLINE: Tolvaptan, Hyponatremia, Antidiuretic Hormone Receptor Antagonists, Fluid Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia, Endocrine Society of Australia, Otsuka Australia Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Current first-line therapy for hyponatremia, fluid restriction (FR), is often unsuccessful. Tolvaptan, an arginine vasopressin V2-receptor antagonist, is effective; however, concerns about plasma sodium (pNa) overcorrection risk have limited its uptake.

Objective

This work aimed to compare the efficacy of tolvaptan and FR, with a prespecified protocol for dextrose 5% intervention if sodium correction targets were exceeded.

Methods

An open-label, randomized trial was conducted at a single-center tertiary hospital, Austin Health, in Melbourne, Australia. Fifty-four hospitalized patients with pNa 115 to 130 mmol/L (mean 124 mmol/L) were enrolled and randomized to tolvaptan 7.5 mg oral daily or FR less than 1000 mL/day (1:1) for 3 days, with daily titration according to pNa response. Main outcome measures included plasma sodium change from day 1 to 4, requirement for intravenous 5% dextrose to prevent or treat overcorrection, symptom measures, and length of hospital stay.

Results

Plasma sodium concentrations increased more in the tolvaptan group, compared to FR, over 3 days (Poverall < .001). The mean adjusted difference in pNa between groups at days 2, 3, and 4 was 3.2 (95% CI, 1.6-4.7), 3.5 (95% CI, 1.9-5.2), and 2.5 mmol/L (95% CI, 0.8-4.2), respectively. Five tolvaptan recipients (19%) required dextrose 5% to treat rapid sodium increase. With this intervention, no patient had an Na increase more than10 mmol/L at 24 hours. There was no difference in length of stay or symptoms.

Conclusion

Tolvaptan was superior to FR at raising pNa over 3 days. However, intervention was required to prevent overcorrection in some, with no benefit in secondary outcomes. This is the first prospectively validated protocol to detect and prevent tolvaptan-related overcorrection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanHyponatremiaAntidiuretic Hormone Receptor AntagonistsFluid TherapyHumansFemaleMaleMiddle AgedAgedSodiumTreatment OutcomeAdultAged, 80 and over

Stichwörter der Autor:innen

SIADHfluid restrictionhyponatraemiahyponatremiasyndrome of inappropriate antidiuresis (SIAD)tolvaptan

Substanzen

TolvaptanAntidiuretic Hormone Receptor AntagonistsSodium

Autor:innen und Institutionen

  • Austin Health Department of Endocrinology, Austin Health, Heidelberg, VIC 3084, Australia.
  • University of Melbourne Department of Medicine, Austin Health, Heidelberg, VIC 3084, Australia.
  • Alfred Health Department of Endocrinology and Diabetes, Alfred Health, Melbourne, VIC 3004, Australia.

ORCID-Profile: Annabelle M Warren, Mathis Grossmann, Rudolf Hoermann, Rose Lin, Jeffrey D Zajac, Nicholas Russell

Förderung

  • National Health and Medical Research Council of Australia
  • Endocrine Society of Australia
  • Otsuka Australia Pharmaceutical

Zitieren

APA

Warren, A. M., Grossmann, M., Hoermann, R., Lin, R., Zajac, J. D., & Russell, N. (2026). Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism, 111(2), 341-347. https://doi.org/10.1210/clinem/dgaf428

Vancouver

Warren AM, Grossmann M, Hoermann R, Lin R, Zajac JD, Russell N. Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 2026;111(2):341-347. doi:10.1210/clinem/dgaf428

BibTeX
@article{Warren2026,
  author = {Warren, Annabelle M and Grossmann, Mathis and Hoermann, Rudolf and Lin, Rose and Zajac, Jeffrey D and Russell, Nicholas},
  title = {Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {2},
  pages = {341--347},
  doi = {10.1210/clinem/dgaf428}
}
Kostenlos starten →